Report ID : 10352347 |
Published Date : 21 Mar 2025 |
Report Format : PDF,PPT |
Delivery Timeline :48-72 Business Hours
Global Active Pharmaceutical Ingredients (API) Market Highlights Over 2020 - 2030
The global active pharmaceutical ingredients (API) market is estimated to garner a revenue of USD 331.37 Billion by the end of 2030, by growing at a CAGR of 6.08% over the forecast period, i.e., 2021 – 2030. Moreover, the market generated a revenue of USD 185.23 Billion in the year 2020. The growth of the market can be attributed to the growing concern for the rising prevalence of chronic diseases worldwide, which is driving the need to develop advanced medications to treat these diseases. According to the statistics by the World Health Organization (WHO), in the year 2019, around 17.9 Million people died from cardiovascular diseases (CVDs). Additionally, in the other statistics by the WHO, in the year 2019, around 1.5 Million deaths were caused due to diabetes, while, in the year 2020, cancer accounted for around 10 Million deaths. To treat these chronic diseases specialized drugs are required, which is driving the need for APIs amongst the pharmaceutical drug manufacturers.
-Market.jpg)
CLICK TO DOWNLOAD SAMPLE REPORT
The growth of the market can also be attributed to the increasing demand for generic drugs, backed by the increasing number of generic drug approvals worldwide by governmental authorities. Besides this, the increasing advancements in healthcare, backed by the rising healthcare expenditure, is also expected to create numerous opportunities for the growth of the market. Additionally, the rising focus on the development of precision medicines, along with the rising demand for biosimilar drugs and the emergence of highly potency APIs (HPAPIs) are some of the opportunities anticipated to boost the market growth in the years to come.
Global Active Pharmaceutical Ingredients (API) Market Regional Synopsis
Regionally, the global active pharmaceutical ingredients (API) market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America is anticipated to garner the largest revenue of USD 127.61 Billion by the end of 2030, up from a revenue of USD 71.70 Billion in the year 2020. The growth of the market in the region can be attributed to the presence of a strong healthcare network, along with the rising healthcare expenditure. Moreover, increasing prevalence of chronic diseases in the region, especially in the United States, which according to the statistics by the Centers for Disease Control and Prevention (CDC) recorded having a chronic disease among 6 adults out of 10 adults, and two or more chronic diseases among 4 adults out of 10 adults. The market in the region can further be segmented by country into the United States and Canada. Out of these, the market in the United States is expected to garner the largest revenue by the end of 2030 and also grow with the highest CAGR of 6.03% during the forecast period. On the other hand, the market in the Asia Pacific is anticipated to garner the second-largest revenue of USD 104.98 Billion by the end of 2030. The market in the region is further segmented by country into Japan, Australia, Singapore, South Korea, India, China, and the Rest of Asia Pacific. Out of these, the market in China is projected to generate the largest revenue of USD 36.90 Billion by the end of 2030.
Growth Drivers and Challenges Impacting the Growth of the Global Active Pharmaceutical Ingredients (API) Market
Growth Drivers
-
Rising Prevalence of Chronic and Infectious Diseases Worldwide
-
Increasing Demand for Generic Drugs
Challenges
-
High Cost of Manufacturing of APIs
Global Active Pharmaceutical Ingredients (API) Market Segmentation Synopsis
The global active pharmaceutical ingredients (API) market is segmented by type into generic, and innovative, out of which, the generic segment is projected to grow with the highest CAGR of 6.28% during the forecast period. Further, by synthesis type, the market is segmented into synthetic and biotech, out of which, the synthetic segment is projected to garner the largest revenue by the end of 2030. By therapeutic application, the market is segmented into communicable disease, oncology, diabetes, cardiovascular disease, musculoskeletal disorders, respiratory disorders, and other therapeutic applications. Out of these, the cardiovascular disease segment is anticipated to garner the largest revenue of USD 68.81 Billion by the end of 2030, up from a revenue of USD 39.50 Billion in the year 2020. Additionally, by business mode, the market is segmented into captive and merchant, out of which, the merchant segment is expected to grow with the highest CAGR of 6.22% during the forecast period.
Key Companies Dominating the Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global active pharmaceutical ingredients (API) market that are included in our report are Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Sanofi-aventis Groupe, Boehringer Ingelheim International GmbH, Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., API Corporation, Bristol-Myers Squibb Company, KATSURA CHEMICAL CO., LTD., and others.
Latest Developments in the Global Active Pharmaceutical Ingredients (API) Market:
-
May 18th, 2021: Novartis AG announced that its Sandoz division would expand the production capabilities in Kundl, Austria and in Palafolls, Spain. This step of the company is aligned with its plans which was proposed in July 2020, in a collaboration with the Austrian government, that focuses on investing more than USD 118 Million in the first step, for introducing a new manufacturing technology for the production of an API, oral amoxicillin, for its leading penicillin product.
-
June 16th, 2017: Bristol-Myers Squibb Company announced that it has signed a definitive purchase agreement with SK Biotek Co., Ltd., where the latter would purchase the small molecule active pharmaceutical ingredient (API) manufacturing facility of Bristol-Myers Squibb, located in Swords, Ireland.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
1. Market Definition
1.1. Definition
1.2.Market Segmentation
2. Assumptions and Acronyms
3. Research Methodology
3.1.Research Process
3.2. Primary Research
3.3. Secondary Research
4. Executive Summary-Global Active Pharmaceutical Ingredients (API) Market
5. Market Dynamics
5.1. Market Drivers
5.2. Market Trends
6. Key Market Opportunities
7. Major Roadblocks for the Market Growth
8. Regulatory and Standards Landscape
9. Industry Risk Analysis
10. Pricing Analysis of Active Pharmaceutical Ingredients (API) Market
11. Industry Value Chain Analysis
12.Trade Outlook
12.1. Import
12.2. Export
13.Impact of COVID-19 on the Active Pharmaceutical Ingredients (API) Market
14.Product Feature Analysis
15. Competitive Positioning
16.Competitive Structure
16.1. Market Share Analysis, 2020
16.2. Competitive Benchmarking
16.3. Company Profiles
16.3.1. Pfizer Inc.
16.3.2. GlaxoSmithKline plc
16.3.3. Novartis AG
16.3.4. Sanofi-aventis Groupe
16.3.5. Boehringer Ingelheim International GmbH
16.3.6. Aurobindo Pharma
16.3.7. Dr. Reddy’s Laboratories Ltd.
16.3.8. API Corporation
16.3.9. Bristol-Myers Squibb Company
16.3.10. KATSURA CHEMICAL CO., LTD.
17. Global Active Pharmaceutical Ingredients (API) Market Outlook
17.1. Market by Value (USD Billion)
17.2. Market Segmentation
17.2.1. By Type
17.2.1.1. Generic, 2020-2030F (USD Billion)
17.2.1.2. Innovative, 2020-2030F (USD Billion)
17.2.2. By Synthesis Type
17.2.2.1. Synthetic, 2020-2030F (USD Billion)
17.2.2.2. Biotech, 2020-2030F (USD Billion)
17.2.3. By Therapeutic Application
17.2.3.1. Communicable Diseases, 2020-2030F (USD Billion)
17.2.3.2. Oncology, 2020-2030F (USD Billion)
17.2.3.3. Diabetes, 2020-2030F (USD Billion)
17.2.3.4. Cardiovascular Disease, 2020-2030F (USD Billion)
17.2.3.5. Musculoskeletal Disorders, 2020-2030F (USD Billion)
17.2.3.6. Respiratory Diseases, 2020-2030F (USD Billion)
17.2.3.7. Other Therapeutic Applications, 2020-2030F (USD Billion)
17.2.4. By Business Mode
17.2.4.1. Captive, 2020-2030F (USD Billion)
17.2.4.2. Merchant, 2020-2030F (USD Billion)
17.2.5. By Region
17.2.5.1. North America, 2020-2030F (USD Billion)
17.2.5.2. Europe, 2020-2030F (USD Billion)
17.2.5.3. Asia Pacific, 2020-2030F (USD Billion)
17.2.5.4. Latin America, 2020-2030F (USD Billion)
17.2.5.5. Middle East & Africa, 2020-2030F (USD Billion)
18.North America Active Pharmaceutical Ingredients (API) Market Outlook
18.1. Market by Value (USD Billion)
18.2. Market Segmentation
18.2.1. By Type
18.2.1.1. Generic, 2020-2030F (USD Billion)
18.2.1.2. Innovative, 2020-2030F (USD Billion)
18.2.2. By Synthesis Type
18.2.2.1. Synthetic, 2020-2030F (USD Billion)
18.2.2.2. Biotech, 2020-2030F (USD Billion)
18.2.3. By Therapeutic Application
18.2.3.1. Communicable Diseases, 2020-2030F (USD Billion)
18.2.3.2. Oncology, 2020-2030F (USD Billion)
18.2.3.3. Diabetes, 2020-2030F (USD Billion)
18.2.3.4. Cardiovascular Disease, 2020-2030F (USD Billion)
18.2.3.5. Musculoskeletal Disorders, 2020-2030F (USD Billion)
18.2.3.6. Respiratory Diseases, 2020-2030F (USD Billion)
18.2.3.7. Other Therapeutic Applications, 2020-2030F (USD Billion)
18.2.4. By Business Mode
18.2.4.1. Captive, 2020-2030F (USD Billion)
18.2.4.2. Merchant, 2020-2030F (USD Billion)
18.2.5. By Country
18.2.5.1. United States, 2020-2030F (USD Billion)
18.2.5.2. Canada, 2020-2030F (USD Billion)
19.Europe Active Pharmaceutical Ingredients (API) Market Outlook
19.1. Market by Value (USD Billion)
19.2. Market Segmentation
19.2.1. By Type
19.2.2. By Synthesis Type
19.2.3. By Therapeutic Application
19.2.4. By Business Mode
19.2.5. By Country
19.2.5.1. United Kingdom, 2020-2030F (USD Billion)
19.2.5.2. Germany, 2020-2030F (USD Billion)
19.2.5.3. Italy, 2020-2030F (USD Billion)
19.2.5.4. France, 2020-2030F (USD Billion)
19.2.5.5. Spain, 2020-2030F (USD Billion)
19.2.5.6. Russia, 2020-2030F (USD Billion)
19.2.5.7. Netherlands, 2020-2030F (USD Billion)
19.2.5.8. Rest of Europe, 2020-2030F (USD Billion)
20. Asia Pacific Active Pharmaceutical Ingredients (API) Market Outlook
20.1. Market by Value (USD Billion)
20.2. Market Segmentation
20.2.1. By Type
20.2.2. By Synthesis Type
20.2.3. By Therapeutic Application
20.2.4. By Business Mode
20.2.5. By Country
20.2.5.1. Japan, 2020-2030F (USD Billion)
20.2.5.2. Australia, 2020-2030F (USD Billion)
20.2.5.3. Singapore, 2020-2030F (USD Billion)
20.2.5.4. South Korea, 2020-2030F (USD Billion)
20.2.5.5. India, 2020-2030F (USD Billion)
20.2.5.6. China, 2020-2030F (USD Billion)
20.2.5.7. Rest of Asia Pacific, 2020-2030F (USD Billion)
21.Latin America Active Pharmaceutical Ingredients (API) Market Outlook
21.1. Market by Value (USD Billion)
21.2. Market Segmentation
21.2.1. By Type
21.2.2. By Synthesis Type
21.2.3. By Therapeutic Application
21.2.4. By Business Mode
21.2.5. By Country
21.2.5.1. Brazil, 2020-2030F (USD Billion)
21.2.5.2. Argentina, 2020-2030F (USD Billion)
21.2.5.3. Mexico, 2020-2030F (USD Billion)
21.2.5.4. Rest of Latin America, 2020-2030F (USD Billion)
22. Middle East & Africa Active Pharmaceutical Ingredients (API) Market Outlook
22.1. Market by Value (USD Billion)
22.2. Market Segmentation
22.2.1. By Type
22.2.2. By Synthesis Type
22.2.3. By Therapeutic Application
22.2.4. By Business Mode
22.2.5. By Country
22.2.5.1. GCC, 2020-2030F (USD Billion)
22.2.5.2. Israel, 2020-2030F (USD Billion)
22.2.5.3. South Africa, 2020-2030F (USD Billion)
22.2.5.4. Rest of Middle East & Africa, 2020-2030F (USD Billion)
